New York City-based AiCure is launching a clinical trial to validate its video-based approach to medication adherence. The company will work with the Cincinnati Addiction Research Center (CinARC) at the University of Cincinnati on a 12-month, 130-patient trial.
AiCure is a novel medication adherence company in terms of its approach: the company uses a tablet or smartphone’s camera to observe the patient taking medications. An artificial intelligence system analyzes the video to make sure the patient took the medication correctly and sends an alert if they didn’t.
“If this is deployed in a health system, you can actually monitor the performance and medication adherence rates of someone suffering from mental illness, and you can see whether they’re adherent or not,” CEO Adam Hanina told MobiHealthNews in an interview last year. “And in the event that they’re not adherent there will be an escalation protocol, a reminder on their device. And then after a day or two that can get escalated to actually get a phone call from the outreach team.”
The technology is particularly well-suited for work with patients taking opiates, Hanina told MobiHealthNews in an email, because it’s a use case that requires highly accurate monitoring.
“Unlike many other technologies that rely on approximate measures of adherence, such as pill counts, self-reported text messages, electronic patient diaries, electronic pill bottles, and so forth, AiCure uses facial recognition and motion-sensing technology to confirm a patient has correctly taken their medication — thereby the actual activity of taking the medication is the check mark,” he wrote. “For a patient population where adherence to treatment is critical, where the cost of nonadherence is particularly high (both in terms of health outcomes and actual cost), and where an exact measure of adherence is required, i.e. every dose is accounted for, AiCure is ideally suited as a treatment monitoring solution.” Keep reading>>